Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals Inc.

Wells Fargo analyst maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $100.00. In addition to Wells Fargo, Ionis Pha...

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals (IONS) and Guardant Health (GH). Ionis Phar...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Guardant Health (GH)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $90.00. According t...

Barclays Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals ( ($IONS) ) just unveiled an update. Ionis Pharmaceuticals and AstraZeneca reported on July 9, 2026, that the large Phase 3 C...

Ionis, AstraZeneca report Phase 3 eplontersen setback

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Natera (NTRA) and Ionis Pharmaceuticals (IONS) with ...

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS) and Alnylam Pharma (ALN...

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Alnylam Pharma (ALNY)

AstraZeneca stock was down on Thursday after it reported a failed clinical trial, but this could present a buying opportunity for investors.


Is AstraZeneca (AZN) Stock a Buy on Today’s Dip? Here’s What Analysts Have to Say About That

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and Ionis Pharmaceuticals (IONS) with ...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MiMedx Group (MDXG), Climb Bio (CLYM) and Ionis Phar...

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), Climb Bio (CLYM) and Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS) and uniQure (QURE) with...

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inmune Bio (INMB), AbSci (ABSI) and Ionis Pharmaceut...

Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)

Ionis Pharmaceuticals Inc. ($IONS) announced an update on their ongoing clinical study. The study titled A Phase 2, Open-label Trial Evaluating the...

Ionis Advances ION775 Phase 2 Trial in High Triglycerides: What Investors Should Watch

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (I...

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (IONS) and Rhythm Pharmaceuticals (RYTM)

In a report released yesterday, Yaron Werber from TD Cowen reiterated a Buy rating on Ionis Pharmaceuticals, with a price target of $108.00. Werber...

TD Cowen Remains a Buy on Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals ( ($IONS) ) has provided an update. On June 12, 2026, Ionis Pharmaceuticals reported positive new data from its CORE-OLE open...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IONS	$58.25	-9.37%	11.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IONS	$58.25	-9.4%	11.44M
3
4
5
6

IONS

IONS

Get Ionis Pharmaceuticals Inc. Data in Excel

Get Ionis Pharmaceuticals Inc. Data in Excel